A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)

被引：2
|
作者：
Hurvitz, Sara A.
Schilder, Jeanne Marie
Frenzel, Martin
Martin, Miguel
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT092
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review
    Carter, Gebra Cuyun
    Mohanty, Maitreyee
    Stenger, Keri
    Guimaraes, Claudia Morato
    Singuru, Shivaprasad
    Basa, Pradeep
    Singh, Sheena
    Tongbram, Vanita
    Kuemmel, Sherko
    Guarneri, Valentina
    Tolaney, Sara M.
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6537 - 6566
  • [22] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
    Slamon, Dennis J.
    Fasching, Peter A.
    Patel, Ravindranath
    Verma, Sunil
    Hurvitz, Sara A.
    Chia, Stephen K. L.
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Spera, Gonzalo
    Lopez, Celine
    Hor, Ines
    Pelov, Diana
    Hughes, Gareth
    Nawinne, Moditha
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [24] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [25] A PHASE II STUDY OF METRONOMIC DAILY ORAL VINORELBINE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC HORMONE RECEPTOR POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) BREAST CANCER RESISTANT TO ENDOCRINE THERAPY: VINOMETRO
    Thomssen, Christoph
    Decker, Thomas
    Fehm, Tanja
    Fuxius, Stefan
    Harbeck, Nadia
    Juhasz-Boess, Ingolf
    Moebus, Volker
    Seehase, Martina
    Schollenberger, Lukas
    Ruckes, Christian
    Schmidt, Marcus
    BREAST, 2017, 36 : S51 - S51
  • [26] Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer
    Hurvitz, S.
    Martin, M.
    Press, M.
    Wijayawardana, S.
    Brahmachary, M.
    Ebert, P. J.
    Young, S.
    Jansen, V.
    Slamon, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [28] VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy
    Elger, T.
    Decker, T.
    Fehm, T.
    Fuxius, S.
    Harbeck, N.
    Juhasz-Boess, I.
    Moebus, V.
    Thomssen, C.
    Seehase, M.
    Schollenberger, L.
    Ruckes, C.
    Schmidt, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus ) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro
    Schmidt, Marcus
    Decker, Thomas
    Fehm, Tanja
    Fuxius, Stefan
    Harbeck, Nadia
    Juhasz-Boess, Ingolf
    Thomssen, Christoph
    Seehase, Martina
    Schollenberger, Lukas
    Ruckes, Christian
    Moebus, Volker
    CANCER RESEARCH, 2018, 78 (04)
  • [30] A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
    Andre, F.
    Kaufman, B.
    Juric, D.
    Ciruelos, E.
    Iwata, H.
    Mayer, I. A.
    Conte, P.
    Rugo, H. S.
    Loibl, S.
    Rubovszky, G.
    Tesch, H.
    Inoue, K.
    Lu, Y-S.
    Ryvo, L.
    Longin, A-S.
    Mills, D.
    Wilke, C.
    Germa, C.
    Campone, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345